Diabetes and hypertension are closely interlinked and among the most prevalent diseases that significantly increase cardiovascular risks. They can be caused by a wide range of factors, which often affect overlapping molecular pathways, resulting in vascular dysfunction. Hyperglycemia in diabetes and increased angiotensin II levels in hypertension act similarly to promote vascular dysfunction by triggering pathways leading to oxidative stress, low-grade inflammation, and vessel remodeling. In this context, Heat Shock Protein 70 (HSP70), a ubiquitous molecular chaperone that exists locally (iHSP70) and systemically (eHSP70) and has opposing biological effects, is emerging as a new component associated with vascular dysfunction in chronic conditions. While elevated levels of eHSP70 in diabetes and hypertension have been associated with low-grade inflammation, iHSP70 appears to regulate intracellular calcium handling—a hallmark mechanism disrupted in both pathologies. This review focuses on the role of HSP70 as an evolving component of the intricate mechanisms underlying vascular dysfunction in these two pervasive diseases, which are very likely to coexist and represent a growing burden worldwide, while addressing whether HSP70 actively contributes to the vascular dysfunction or reflects an adaptive response to disease-associated stress across tissues and experimental models. Finally, we discuss emerging evidence on the pharmacological modulation of HSP70 and the challenges remaining in defining its role as a biomarker and therapeutic target.
23 June 2026 in European Journal of Drug Metabolism and Pharmacokinetics
Efavirenz is associated with frequent adverse effects, mainly hepatotoxicity and central nervous system disturbances. The cytochrome P450 enzyme CYP2B6 plays a key role in efavirenz metabolism and is strongly linked to these toxicities. This study aimed to evaluate the effect of the CYP2B6 c.516 G>T polymorphism on efavirenz plasma concentrations by comparing individuals with GG, GT, and TT genotypes. A systematic review of four databases was conducted to identify studies published up to March 2025 evaluating the association between the CYP2B6 c.516 G>T polymorphism and efavirenz plasma concentrations. Pooled mean differences with 95% confidence intervals were calculated using random-effects models. Five studies, including 373 patients, met the inclusion criteria. Individuals with the TT genotype showed significantly higher plasma efavirenz concentrations compared with GG and GT carriers. The mean differences in plasma concentration between the GT-TT and GG-TT subgroups were 5.65 µg/mL and 6.41 µg/mL, respectively, both statistically significant (p < 0.05). No significant difference was observed between the GG and GT genotypes. This meta-analysis confirms that the CYP2B6 c.516 TT genotype is significantly associated with elevated plasma efavirenz concentration in patients with HIV and tuberculosis. While higher concentrations may increase toxicity risk, this was not directly evaluated in the current pooled analysis. These findings support the potential utility of pharmacogenetic testing to optimize efavirenz dosing and minimize the risk of adverse effects, particularly in carriers of the TT genotype. The observed heterogeneity among studies may be attributed to ethnic variability and differences in sample sizes.